newsfilter
← Latest News
Business Wire·

Baxalta to Initiate a First-in-Human Clinical Trial of BAX 826, an Investigational, Extended Half-Life FVIII Treatment Targeting Weekly Dosing for Hemophilia A

BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced the submission of a Clinical Trial Application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a first-in-human clinical trial to evaluate the safety and efficacy of BAX 826, an investigational, extended half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A.